Home > Newsletters > Drug Industry Daily > Novartis’ Afinitor Gets Fifth Indication as Advanced Breast Cancer Treatment
Drug Industry Daily
July 23, 2012 | Vol. 11 No. 143
Novartis’ Afinitor Gets Fifth Indication as Advanced Breast Cancer Treatment
The FDA has approved Novartis’ Afinitor to treat postmenopausal women with advanced hormone receptor-positive (HR+), HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole, marking the fifth indication for the drug.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.